Details for Patent: 11,643,397

Which drugs does patent 11,643,397 protect, and when does it expire?

Patent 11,643,397 protects JESDUVROQ and is included in one NDA.

This patent has thirty-six patent family members in thirty-one countries.

Summary for Patent: 11,643,397

Title:	Prolyl hydroxylase inhibitors
Abstract:	The invention described herein relates to certain pyrimidinetrione N-substituted glycine derivatives of formula (I)which are antagonists of HIF prolyl hydroxylases and are useful for treating diseases benefiting from the inhibition of this enzyme, anemia being one example.
Inventor(s):	Kevin J. Duffy, Duke M. FITCH, Jian Jin, Ronggang Liu, Antony N. Shaw, Kenneth Wiggall
Assignee:	GlaxoSmithKline LLC
Application Number:	US17/383,554
Patent Claim Types: see list of patent claims	Use;

Drugs Protected by US Patent 11,643,397

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Glaxosmithkline	JESDUVROQ	daprodustat	TABLET;ORAL	216951-001	Feb 1, 2023		DISCN	Yes	No	11,643,397			Y		A METHOD OF TREATING ANEMIA
Glaxosmithkline	JESDUVROQ	daprodustat	TABLET;ORAL	216951-002	Feb 1, 2023		DISCN	Yes	No	11,643,397			Y		A METHOD OF TREATING ANEMIA
Glaxosmithkline	JESDUVROQ	daprodustat	TABLET;ORAL	216951-003	Feb 1, 2023		DISCN	Yes	No	11,643,397			Y		A METHOD OF TREATING ANEMIA
Glaxosmithkline	JESDUVROQ	daprodustat	TABLET;ORAL	216951-004	Feb 1, 2023		DISCN	Yes	No	11,643,397			Y		A METHOD OF TREATING ANEMIA
Glaxosmithkline	JESDUVROQ	daprodustat	TABLET;ORAL	216951-005	Feb 1, 2023		DISCN	Yes	No	11,643,397			Y		A METHOD OF TREATING ANEMIA

International Family Members for US Patent 11,643,397

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	061570
Australia	2007260837
Brazil	PI0713446
Canada	2655491
China	101505752